MicroRNA expression is deregulated by aberrant methylation in B-cell acute lymphoblastic leukemia mouse model

Wang, Yidan; Wang, Yihan; Hui, Hetong; Fan, Xinyuan; Wang, Tianqi; Xia, Wei; Liu, LiMei

doi:10.1007/s11033-021-06982-x

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since methylation changes commonly occur in the early stages of cancer, systematic analysis of the methylation profile of serum cell-free DNA (cfDNA) is being developed for early detection of cancer, monitoring of minimal residual disease, prediction of treatment response and prognosis and tracking tissue origin. 26,27 Considering these findings and aiming to elucidate the function, underlying mechanism and early diagnostic value of CDO1 in BC, we conducted bioinformatics analysis of publicly available databases and MassARRAY Epi-TYPER methylation sequencing to identify differentially methylated sites in the CDO1 promoter region between BC tissues and normal adjacent tissues (NATs). The Methy-Light assay was then developed with specific primers and probes designed for those CpG sites to detect the percent of methylated reference (PMR) of CDO1 promoter in two cohorts: cohort I of tissue and cohort II of serum, and the early diagnostic value of serum CDO1 PMR were then evaluated.…”

Section: Correspondencementioning

confidence: 99%

“…Therefore, novel non‐invasive biomarkers, particularly for early‐stage BC identification, are needed. Since methylation changes commonly occur in the early stages of cancer, systematic analysis of the methylation profile of serum cell‐free DNA (cfDNA) is being developed for early detection of cancer, monitoring of minimal residual disease, prediction of treatment response and prognosis and tracking tissue origin 26,27 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells

Yang,

Sun,

Liu

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

BackgroundCysteine dioxygenase 1 (CDO1) is frequently methylated, and its expression is decreased in many human cancers including breast cancer (BC). However, the functional and mechanistic aspects of CDO1 inactivation in BC are poorly understood, and the diagnostic significance of serum CDO1 methylation remains unclear.MethodsWe performed bioinformatics analysis of publicly available databases and employed MassARRAY EpiTYPER methylation sequencing technology to identify differentially methylated sites in the CDO1 promoter of BC tissues compared to normal adjacent tissues (NATs). Subsequently, we developed a MethyLight assay using specific primers and probes for these CpG sites to detect the percentage of methylated reference (PMR) of the CDO1 promoter. Furthermore, both LentiCRISPR/dCas9‐Tet1CD‐based CDO1‐targeted demethylation system and CDO1 overexpression strategy were utilized to detect the function and underlying mechanism of CDO1 in BC. Finally, the early diagnostic value of CDO1 as a methylation biomarker in BC serum was evaluated.ResultsCDO1 promoter was hypermethylated in BC tissues, which was related to poor prognosis (p < .05). The CRISPR/dCas9‐based targeted demethylation system significantly reduced the PMR of CDO1 promotor and increased CDO1 expression in BC cells. Consequently, this leads to suppression of cell proliferation, migration and invasion. Additionally, we found that CDO1 exerted a tumour suppressor effect by inhibiting the cell cycle, promoting cell apoptosis and ferroptosis. Furthermore, we employed the MethyLight to detect CDO1 PMR in BC serum, and we discovered that serum CDO1 methylation was an effective non‐invasive biomarker for early diagnosis of BC.ConclusionsCDO1 is hypermethylated and acts as a tumour suppressor gene in BC. Epigenetic editing of abnormal CDO1 methylation could have a crucial role in the clinical treatment and prognosis of BC. Additionally, serum CDO1 methylation holds promise as a valuable biomarker for the early diagnosis and management of BC.

show abstract

Section: Correspondencementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells

Yang,

Sun,

Liu

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

Dysregulation of Serum MicroRNA after Intracerebral Hemorrhage in Aged Mice

et al. 2023

View full text Add to dashboard Cite

Stroke is one of the most common diseases that leads to brain injury and mortality in patients, and intracerebral hemorrhage (ICH) is the most devastating subtype of stroke. Though the prevalence of ICH increases with aging, the effect of aging on the pathophysiology of ICH remains largely understudied. Moreover, there is no effective treatment for ICH. Recent studies have demonstrated the potential of circulating microRNAs as non-invasive diagnostic and prognostic biomarkers in various pathological conditions. While many studies have identified microRNAs that play roles in the pathophysiology of brain injury, few demonstrated their functions and roles after ICH. Given this significant knowledge gap, the present study aims to identify microRNAs that could serve as potential biomarkers of ICH in the elderly. To this end, sham or ICH was induced in aged C57BL/6 mice (18–24 months), and 24 h post-ICH, serum microRNAs were isolated, and expressions were analyzed. We identified 28 significantly dysregulated microRNAs between ICH and sham groups, suggesting their potential to serve as blood biomarkers of acute ICH. Among those microRNAs, based on the current literature, miR-124-3p, miR-137-5p, miR-138-5p, miR-219a-2-3p, miR-135a-5p, miR-541-5p, and miR-770-3p may serve as the most promising blood biomarker candidates of ICH, warranting further investigation.

show abstract

MicroRNA expression is deregulated by aberrant methylation in B-cell acute lymphoblastic leukemia mouse model

Cited by 2 publications

References 37 publications

Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells

Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells

Dysregulation of Serum MicroRNA after Intracerebral Hemorrhage in Aged Mice

Contact Info

Product

Resources

About